Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Femasys ( (FEMY) ) has provided an update.
On July 16, 2025, Femasys Inc. was notified by Nasdaq that its common stock had failed to meet the $1.00 per share minimum bid price requirement for 30 consecutive business days, triggering a potential delisting process. The company initially had until January 12, 2026, to regain compliance, and on that date it requested a 180-day extension, citing stockholders’ equity of more than $5 million as of December 31, 2025, and its intention to cure the deficiency, if needed, through a reverse stock split. On January 13, 2026, Nasdaq granted Femasys an extension until July 13, 2026, to restore its share price to at least $1.00 for ten consecutive business days, and the company plans to closely monitor its stock and consider options such as a reverse split to maintain its Nasdaq listing, a step that could affect shareholders and its market standing.
The most recent analyst rating on (FEMY) stock is a Sell with a $0.54 price target. To see the full list of analyst forecasts on Femasys stock, see the FEMY Stock Forecast page.
Spark’s Take on FEMY Stock
According to Spark, TipRanks’ AI Analyst, FEMY is a Neutral.
The score is held down primarily by weak financial performance (ongoing losses and negative cash flow) and bearish technical signals (below key moving averages with negative MACD). Offsetting these risks, recent FDA/regulatory and early commercialization events are constructive, but not enough to outweigh the current financial and trend headwinds.
To see Spark’s full report on FEMY stock, click here.
More about Femasys
Average Trading Volume: 6,293,924
Technical Sentiment Signal: Strong Sell
Current Market Cap: $41.06M
See more insights into FEMY stock on TipRanks’ Stock Analysis page.